How does Novo Nordisk navigate the ethics of selling diabetes meds?

Novo Nordisk ($NVO) CEO Lars Sorensen explains his worldwide pricing strategy for diabetes drugs: dirt cheap in the poorest countries, inexpensive to not-so-much in the midrange, with U.S., Europe and Japan paying the most, because they focus on the newest products. Report